姓 名:夏雪山
出生年月:1971年10月
碩導(dǎo)/博導(dǎo):碩士、博士研究生導(dǎo)師
學(xué) 位:博士研究生
所屬科室:基礎(chǔ)醫(yī)學(xué)院 病原生物學(xué)與免疫學(xué)系
職 務(wù): 昆明醫(yī)科大學(xué) 校長(zhǎng)
所獲獎(jiǎng)項(xiàng):獲云南省科技進(jìn)步獎(jiǎng)一等獎(jiǎng),、云南省自然科學(xué)獎(jiǎng)二等獎(jiǎng)等省部獎(jiǎng)勵(lì)5項(xiàng)。
招生專業(yè):病原生物學(xué)
研究領(lǐng)域:分子病毒學(xué)
社會(huì)兼職:云南省免疫學(xué)會(huì)理事長(zhǎng),、云南省微生物學(xué)會(huì)副理事長(zhǎng)
其他介紹:國(guó)家重點(diǎn)研發(fā)計(jì)劃首席科學(xué)家,,享受國(guó)務(wù)院特殊津貼,,云南省 “興滇英才支持計(jì)劃”云嶺學(xué)者,云南省有突出貢獻(xiàn)優(yōu)秀專業(yè)技術(shù)人才,。發(fā)表論文300余篇,,其中SCI文章182篇;出版專著3部,;授權(quán)發(fā)明專利15項(xiàng),。獲云南省科技進(jìn)步獎(jiǎng)一等獎(jiǎng)、云南省自然科學(xué)獎(jiǎng)二等獎(jiǎng)等省部獎(jiǎng)勵(lì)5項(xiàng),。
主持或參加科研項(xiàng)目及人才計(jì)劃項(xiàng)目情況(按時(shí)間倒序排序):
1.國(guó)家重點(diǎn)研發(fā)計(jì)劃項(xiàng)目:2023YFC2307400,,“入境人群重大傳染病快速排查關(guān)鍵技術(shù)研究與應(yīng)用示范”,2023.12-2026.11,,1500萬(wàn)元,,在研,主持,。
2.云南省公共衛(wèi)生與生物安全重點(diǎn)實(shí)驗(yàn)室,,202402AN360004,2024.01-2025.12,,200萬(wàn),,在研,主持,。
3.云南省胃癌發(fā)生關(guān)鍵分子發(fā)現(xiàn)與檢測(cè)技術(shù)國(guó)際聯(lián)合實(shí)驗(yàn)室,,202303AP140017,2023.01-2025.12,,300萬(wàn)元,,在研,主持,。
代表性成果:
一,、期刊論文:
1) Zhao C#, Yan S#, Luo Y, Song Y*, Xia X*. Analyzing resistome in soil and Human gut: a study on the characterization and risk evaluation of antimicrobial peptide resistance. Front Microbiol. 2024;15:1352531.
2) Huang X#, Hou J#, Le X, Hou Y, Yang L, Li Q, Wang B*, Xia X*. Diversity of astroviruses in wild animals in Yunnan province, China. Virol J. 2024;21(1):51.
3) Fan Y#, Hou Y#, Li Q, Dian Z, Wang B*, Xia X*. RNA virus diversity in rodents. Arch Microbiol. 2023;206(1):9.
4) Shah T#, Hou Y#, Jiang J, Shah Z, Wang Y, Li Q, Xu X, Wang Y, Wang B*, Xia X*. Comparative analysis of the intestinal microbiome in Rattus norvegicus from different geographies. Front Microbiol. 2023;14:1283453.
5) Liu L#, Li M#, Liu G#, He J, Liu Y, Chen X, Tu Y, Lin J, Feng Y*, Xia X*. A novel, highly sensitive, one-tube nested quantitative real-time PCR for Brucella in human blood samples. Microbiol Spectr. 2023;11(6):e0058223.
6) Liu M#, Zhao T#, Zhang Y, Zhang AM, Geng J*, Xia X*. The incidence of hepatocellular carcinoma and clearance of hepatitis B surface for CHB patients in the indeterminate phase: a systematic review and meta-analysis. Front Cell Infect Microbiol. 2023;13:1226755.
7) Shah T#, Wang Y#, Wang Y, Li Q, Zhou J, Hou Y, Wang B*, Xia X*. A Comparative Analysis of the Stomach, Gut, and Lung Microbiomes in Rattus norvegicus. Microorganisms. 2023;11(9):2359.
8) Jia Y#, Zou X#, Yue W#, Liu J, Yue M, Liu Y, Liu L, Huang P, Feng Y, Xia X*. The distribution of hepatitis C viral genotypes shifted among chronic hepatitis C patients in Yunnan, China, between 2008-2018. Front Cell Infect Microbiol. 2023;13:1092936.
9) Shah T#, Li Q#, Wang B, Baloch Z, Xia X*. Geographical distribution and pathogenesis of ticks and tick-borne viral diseases. Front Microbiol. 2023;14:1185829.
10) Mahmood F#, Xu R#, Awan MUN, Jia T, Zhang T, Shi W, Liu M, Han Q, Zhu Q, Zhang Q, Song Y, Xia X*, Zhang J*. Transcriptomics based identification of S100A3 as the key anti-hepatitis B virus factor of 16F16. Biomed Pharmacother. 2023;163:114904.
11) Qu L#, Li X#, Huang B, Liu Y, Li Q, Shah T, Ning Y, Li J, Lu Y, Yan L, Wang B*, Xia X*. Identification and Characterization of Jingmen Tick Virus in Ticks from Yunnan Imported Cattle. Vector Borne Zoonotic Dis. 2023;23(5):298-302.
12) Liu J#, Li J#, Wang B, Liu Y, Liu L, Liu Y, Feng Y, Qin W*, Xia X*. Characterization of a newly emerging HCV subtype 6xk among Burmese travelers arriving at Ruili Port in Yunnan, China. J Infect. 2023;87(1):72-75.
13) Zhang L#, Ye X#, Liu Y, Zhang Z, Xia X*, Dong S*. Research progress on the effect of traditional Chinese medicine on the activation of PRRs-mediated NF-κB signaling pathway to inhibit influenza pneumonia. Front Pharmacol. 2023;14:1132388.
14) Li Q#, Shah T#, Wang B, Qu L, Wang R, Hou Y, Baloch Z, Xia X*. Cross-species transmission, evolution and zoonotic potential of coronaviruses. Front Cell Infect Microbiol. 2023;12:1081370.
二、獎(jiǎng)勵(lì):
1) 夏雪山,,第一獲獎(jiǎng)人,,云南省科技進(jìn)步一等獎(jiǎng),云南重要跨境傳染病傳播特性與口岸衛(wèi)生檢疫技術(shù)體系構(gòu)建及應(yīng)用,, 2019,,2018NC211-R-001;
2) 夏雪山,,第一獲獎(jiǎng)人,,云南省自然科學(xué)二等獎(jiǎng),,宿主因素對(duì)慢性丙型肝炎形成的影響及機(jī)制研究, 2021,,2020NA005-R-001,。
三、專利:
1) 夏雪山,,黃怡,,繆志江,馮悅,,劉麗.皰疹病毒八個(gè)型的兩管四重?zé)晒舛縋CR分型檢測(cè)試劑.CN117737307A.2024.03.22.
2) 張阿梅,,孫寧寧,,夏雪山,,董書維.用于檢測(cè)OPAI基因突變位點(diǎn)的引物組合就其應(yīng)用.CN117757927A.2024.03.26
3) 張阿梅,施秋梅,,夏雪山,,董書維.人冠狀病毒主要蛋白酶3CLpro的活性報(bào)告質(zhì)粒及其應(yīng)用.CN117363654A.2024.01.09
4) 馮悅,吳甜,,劉陽(yáng),,劉高文,夏雪山.檢測(cè)肺炎支原體及其大環(huán)內(nèi)酯類藥物耐藥位點(diǎn)的引物組合.CN116287343A.2023.06.23
5) 王炳輝,,寧玉婷,,夏雪山,侯宇彤,,劉麗.一種蜱源荊門蜱病毒基因組擴(kuò)增引物組,、擴(kuò)增方法和應(yīng)用.CN116716437A.2023.09.08
6) 張阿梅,施秋梅,,夏雪山,,董書維.篩選人冠狀病毒主要蛋白酶3CLpro抑制劑的方法.CN116840201A.2023.10.03
7) 夏雪山,張敏,,馮悅,,劉高文. 檢測(cè)集合分枝桿菌氟喹諾酮耐藥突變物組合.CN116769939A.2023.09.19